Hepatitis B Treatment Market Research Report - Forecast till 2030

Hepatitis B Treatment Market Research Report, By Type (Acute and Chronic), Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, and Surgery (Liver Transplant)), and Distribution Channel (Hospital & Retail Pharmacies)- Forecast till 2030

ID: MRFR/HC/6347-HCR | February 2021 | Region: Global | 110 pages

Hepatitis B Treatment Market Speak to Analyst Request a Free Sample

Hepatitis B Treatment Market Scenario


The hepatitis B treatment market is expected to register an approximate CAGR of 5.90% during the forecast period, i.e., from 2020 to 2030.


Hepatitis is a viral infection caused by Hepatitis A, B or C virus. The infection results to cause liver infection or inflammation and many times leading to liver damage.


Hepatitis B virus spreads through coming in contact with infected blood, drinking contaminated water, and using infected needles or syringes.  The person suffering from Hepatitis B faces various symptoms such as poor appetite, weakness, jaundice, dark-colored urine, itching on skin, swelling on legs, weight loss, drowsiness and many more. According to the World Health Organization 2018 fact sheet, it was estimated that 257 million people across the world have lived with hepatitis B infection and also mentioned that around 887,000 number of people died from hepatitis B in 2015. Thus, the increasing prevalence of Hepatitis B across the world boosts market growth.


However, the factors such as side effects associated with treatment and medications hinder the market growth.

Hepatitis B Treatment Market Segmentation


The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.


Based on type, the market is segmented into acute and chronic. On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.


Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Hepatitis B Treatment Market Key players


Some of the key players in the hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.


Hepatitis B Treatment Regional Market Summary

Global Hepatitis B Treatment Market Share (%), by Region, 2017


Hepatitis B Treatment Market


Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation


The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.


Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.


Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.


On the other hand, the Middle East and Africa hold the least share in the hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region.
Hepatitis B Treatment Market, by Type


  • Acute

  • Chronic


Hepatitis B Treatment Market, by Treatment


  • Immune Modulator Drugs

    • Pegylated Interferon

    • Interferon Alpha





  • Antiviral Drugs

    • Tenofovir disoproxil

    • Entecavir

    • Telbivudine

    • Lamivudine

    • Others





  • Vaccine

  • Surgery (Liver Transplant)


Hepatitis B Treatment Market, by Distribution Channel


  • Hospital & Retail Pharmacies

  • Online Pharmacies


Hepatitis B Treatment Market, by Key Players


  • Accord Healthcare Inc.

  • Apotex Corp.

  • Arbutus Biopharma

  • Arrowhead Pharma

  • Aurobindo Pharma Limited

  • Bristol-Myers Squibb Company

  • Gilead Sciences, Inc.

  • GlaxoSmithKline

  • Lupin Pharmaceuticals, Inc.

  • Merck & Co., Inc.

  • Par Pharmaceutical, Inc.

  • Teva Pharmaceuticals

  • Zydus Pharmaceuticals


Intended Audience

  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) companies

  • Medical Research Laboratories



Report Scope:
Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   5.90% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Distribution channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Growing geriatric population
  • Increasing the prevalence of viral infection
  • Growing sexually transmitted diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Hepatitis B Treatment Market is expected to exhibit a strong 5.90% CAGR over the forecast period from 2020 to 2030.

    The rising prevalence of hepatitis B is the major driver for the market.

    The risk of side effects from hepatitis B therapeutics is the key restraint on the global hepatitis B treatment market.

    The Americas dominates the global hepatitis B treatment market.

    Leading players in the hepatitis B treatment market include Accord Healthcare, Bristol-Myers Squibb, Apotex, Aurobindo Pharma, and Merck, among others.